WO2004078921A3 - Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes - Google Patents

Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes Download PDF

Info

Publication number
WO2004078921A3
WO2004078921A3 PCT/US2003/006625 US0306625W WO2004078921A3 WO 2004078921 A3 WO2004078921 A3 WO 2004078921A3 US 0306625 W US0306625 W US 0306625W WO 2004078921 A3 WO2004078921 A3 WO 2004078921A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
alpha
macroglobulin
compositions
cancer
Prior art date
Application number
PCT/US2003/006625
Other languages
French (fr)
Other versions
WO2004078921A2 (en
Inventor
Pramod K Srivastava
Robert J Binder
Original Assignee
Univ Connecticut Health Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut Health Ct filed Critical Univ Connecticut Health Ct
Priority to CA2517274A priority Critical patent/CA2517274C/en
Priority to AU2003225661A priority patent/AU2003225661A1/en
Publication of WO2004078921A2 publication Critical patent/WO2004078921A2/en
Publication of WO2004078921A3 publication Critical patent/WO2004078921A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.
PCT/US2003/006625 2003-02-27 2003-03-05 Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes WO2004078921A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2517274A CA2517274C (en) 2003-02-27 2003-03-05 Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
AU2003225661A AU2003225661A1 (en) 2003-02-27 2003-03-05 Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45075103P 2003-02-27 2003-02-27
US60/450,751 2003-02-27

Publications (2)

Publication Number Publication Date
WO2004078921A2 WO2004078921A2 (en) 2004-09-16
WO2004078921A3 true WO2004078921A3 (en) 2004-12-29

Family

ID=32962526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006625 WO2004078921A2 (en) 2003-02-27 2003-03-05 Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes

Country Status (3)

Country Link
AU (1) AU2003225661A1 (en)
CA (1) CA2517274C (en)
WO (1) WO2004078921A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877204B2 (en) 2003-02-20 2014-11-04 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092474A1 (en) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof
WO2002032923A2 (en) * 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092474A1 (en) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof
WO2002032923A2 (en) * 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BINDER R.J. ET AL.: "Naturally formed or artificially reconstituted non-covalent alpha2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity", CANCER IMMUNITY, vol. 2, 18 December 2002 (2002-12-18), pages 16, XP002965477 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy

Also Published As

Publication number Publication date
AU2003225661A8 (en) 2004-09-28
AU2003225661A1 (en) 2004-09-28
CA2517274A1 (en) 2004-09-16
WO2004078921A2 (en) 2004-09-16
CA2517274C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
WO2003008583A3 (en) Novel compositions and methods for cancer
WO2002088101A3 (en) Inhibitors of bace
WO2002002638A3 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2002008190A3 (en) Novel heteroaryl derivatives and use thereof as anti-tumour agents
WO2004087068A3 (en) Cxcr4 antagonists and methods of their use
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
WO2004074454A3 (en) Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
WO2005120558A3 (en) Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
WO2001083774A3 (en) Novel mutated form of arginine deiminase
WO2000066528A3 (en) Quinones for treatment of diseases
WO2006058720A3 (en) Novel compounds for the treatment of neurological disorders
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2003045230A3 (en) Novel compositions and methods for cancer
MXPA03011466A (en) Macrocycles useful in the treatment of alzheimer's disease.
WO2002100818A3 (en) Aminediols as agents for the treatment of alzheimer's disease
WO2006019685A3 (en) Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production
WO2003057146A3 (en) Novel compositions and methods for cancer
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia
WO2003035837A3 (en) Novel compositions and methods for cancer
WO2004078921A3 (en) Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
WO2003039484A3 (en) Novel compositions and methods for cancer
WO2004078130A3 (en) Posh interacting proteins and related methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN IL IN JP KP KR NO RU SG

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2517274

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP